Admin Posted June 7, 2017 Share Posted June 7, 2017 Abiraterone (Zytiga) is approved for supply on the Australian PBS under the following conditions: Authority Required Castration resistant metastatic carcinoma of the prostate Clinical criteria: • The treatment must be in combination with prednisone or prednisolone, AND • The treatment must not be used in combination with chemotherapy, AND • Patient must have failed treatment with docetaxel due to resistance or intolerance; OR • Patient must be unsuitable for docetaxel treatment on the basis of predicted intolerance to docetaxel, AND • Patient must have a WHO performance status of 2 or less, AND • Patient must not receive PBS-subsidised abiraterone if progressive disease develops while on abiraterone, AND • Patient must not have received prior treatment with enzalutamide; OR • Patient must have developed intolerance to enzalutamide of a severity necessitating permanent treatment withdrawal. (Current 7 June 2017. Check pbs.gov.au for the latest version.) So, for most men, only after treatment fails with the chemotherapy docetaxel. We can assume that the Australian supplier of abirateone (Janssen) will present the results of the latest STAMPEDE and LATITUDE trials to the government's expert committee (the PBAC) suggesting that abiraterone be made available to men on the PBS earlier in treatment. I am not a doctor, but these trial results are reported as being very strong. So it will come down to Janssen agreeing a pricing package with the government, if they can. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.